MENU
 

PRE TAX NTA |$3.75

Value as at close of business on 3 January 2024

The Wellcome Trust’s Nick Moakes made a 100-year bet. It’s paying off

The chief investment officer of the massive charitable fund raised almost $3 billion at ultra-low rates. Sometimes the long view can be the most profitable.

The £36.8 billion ($72 billion) Wellcome Trust’s smartest trade over the last decade wasn’t what it bought but rather what it sold.

With interest rates at their lowest point in a generation, the charitable foundation – started in 1936 with the wealth of pharmaceuticals magnate Henry Wellcome – issued a £750 million, 100-year bond in 2018 and then later a 50-year bond of the same amount in 2021.

The trust locked in interest rates of just 2.5 and 1.5 per cent.

‍“It was a moment in time for us,” Wellcome Trust’s chief investment officer Nick Moakes says. “Our fixed income was eye-wateringly overvalued at that point.”

Indeed. Those securities change hands at 39¢ and 50¢ in the dollar to reflect the upward move in interest rates and the decades of payments that have to be repriced.

But for the Wellcome Trust, that cheap long-term financing has “created vast amounts of value”, says Moakes.

He is among the headline acts at this year’s Sohn Hearts & Minds investment conference, which will be held in Adelaide for the first time. Just 24 hours before he announced his retirement, Moakes offered some insights he has garnered from two decades of running the monster portfolio.

Taking the long view

“If you take a 50-year view on this stuff, which effectively an endowment needs to do, this is noise,” Moakes says of investing Wellcome’s funds. It is the largest financier of scientific research in the United Kingdom after the government – into a sharemarket powered by big tech firms.

Moakes joined Wellcome in 2007, which had £15.1 billion in assets. He took over as CIO in 2017. The portfolio stands at £36.8 billion now, and more than £15 billion has been awarded towards funding health-related scientific projects, including in Australia.

In December, the trust awarded $5.4 million to a University of Sydney team to study how disruptive sleeping patterns could cause depression and mood swings.

Last month, it handed $4.9 million to a University of Melbourne team to study the impact of climate on farmers in Kyrgyzstan in Central Asia.

“What sets us apart from most people running money is that we don’t have any clients,” Moakes says. But that does not make the job simple. Although Wellcome determines how much risk it will take, Moakes says this requires watertight governance to make sure the best decisions are made.

Innovation equals productivity growth equals outsized returns. That equation isn’t going to change, in my view.
— Nick Moakes, CIO of the Wellcome Trust

Wellcome must also stay nimble and liquid enough if a call comes to fund a scientific investment. “I don’t know when the organisation is going to come to us and say that we need to spend a billion dollars really quickly because we can make a huge change to health outcomes,” Moakes says.

Moakes is a globally focused investor but has a deep affinity with Australia and the cause of financing medical research that the Sohn Hearts & Minds event has championed. His grandfather, H.E. Graves, moved to Australia in 1925, spending a decade in the West Australian police force.

Graves returned to Britain in 1935 – having penned a memoir, Who Rides – just in time for the outbreak of World War II. It was also the same time that Henry Wellcome, whose company eventually became part of GlaxoSmithKline, one of the world’s largest pharmaceutical groups, was creating the trust.

For those reasons, Moakes, who has spoken at Sohn’s London event is only too happy to book a flight to Adelaide and make his presentation in November.

The 89-year-old Wellcome Trust is steeped in history and the fund is set up to think and invest for the long run.

Moakes says this translates into an allocation of about 80 per cent to be invested in some form of equity – be it private or public. The high weighting to stocks, he says, is partly a function of the lessons learnt during the 1970s and ’80s of the wealth destruction that high inflation can cause.

‘Tyranny of benchmarks’
“That has dominated my mindset,” he says. “If you’re going to defray the risk of inflation, you need to own real assets. You need to own things where the value of the cash flows of the underlying instruments are going to grow with nominal GDP, rather than be fixed.”

But Moakes is happy not to be in the world of traditional funds management, where outperforming market indices dominated by few companies is becoming more difficult. He calls it the “tyranny of benchmarks,” as the fate of stocks such as Nvidia, Apple and Amazon determine whether fund managers meet performance targets.

“They’re fantastic companies. They’ve been built for nothing, and we’ve owned some of them in quite large sizes,” Moakes says. “But to have a portfolio which is completely focused on those things, which is what you’ve needed, puts you at a real risk of things just reversing. That’s a risk that I don’t think a responsible asset owner is going to take on.”

Where there has been a swift reversal is in private equity and venture capital. Last year, the fund’s £12.8 billion private equity portfolio took a 10.4 per cent hit mainly because of venture-related downward revaluations.

Moakes is confident those venture bets will pay off over the long run.

“The reason we have such a lot in early-stage venture investments is that innovation is increasingly going to drive the global economy,” he says. “The rate of innovation has just been accelerating. That tends to drive you more towards the US which has been the most innovative economy globally.


“Innovation equals productivity growth equals outsized returns. That equation isn’t going to change, in my view.”

Wellcome has also allocated money to hedge funds in the hope they can deliver higher returns. “It’s smart people doing things that we cannot do in a structure that controls the risk for us,” Moakes says.

But do hedge funds deliver the results relative to the fees they charge?

“If you look back through our exposures over time, you will see that in September 2008 we had 23 per cent of our assets in hedge funds. As of the end of last financial year, that was about 10 per cent,” he says.

On the other end of the spectrum, the trust holds about 9 per cent of its assets in cash. “That, in part, reflects the fact that we’ve struggled near term to find things that we want to deploy money into,” the CIO adds.

A cash holding is usually a drag on investment returns, but the overnight cash rate in the UK is 5 per cent. That is double the 100-year rate that Moakes helped lock in less than a decade ago.


This article was originally posted by The Australian Financial Review here. The Australian Financial Review is a media partner of Sohn Hearts & Minds.

Licensed by Copyright Agency. You must not copy this work without permission.

Disclaimer: This material has been prepared by The Australian Financial Review, published on 9 Septemer 2024. HM1 is not responsible for the content of linked websites or content prepared by third party. The inclusion of these links and third-party content does not in any way imply any form of endorsement by HM1 of the products or services provided by persons or organisations who are responsible for the linked websites and third-party content. This information is for general information only and does not consider the objectives, financial situation or needs of any person. Before making an investment decision, you should read the relevant disclosure document (if appropriate) and seek professional advice to determine whether the investment and information is suitable for you.

Recent Posts

Read the latest insights
A curated list of HM1 investor updates, portfolio news and other interesting articles.
Read More
10 top fund managers reveal their long-term stock picks
With valuations stretched and geopolitical tensions high, the new year offers plenty of potholes for investors. 
Rikki Bannan – Don’t get caught up in momentum
Conference Fund Manager Rikki Bannan, Executive Director at IFM Investors, joins Equity Mates to discuss her standout 2023 stock pick, Telix, and explore what opportunities lie ahead.
Professor Jane Butler: Sparking Hope for Spinal Cord Injuries
In this episode of the Hearts & Minds Podcast, we sit down with Professor Jane Butler to discuss her groundbreaking research into spinal cord injuries.
Nick Griffin – The Nvidia story is not over
Nick Griffin, Founding Partner & Chief Investment Officer of Munro Partners joined the Equity Mates podcast in their Summer Series.
 

10 top fund managers reveal their long-term stock picks

With valuations stretched and geopolitical tensions high, the new year offers plenty of potholes for investors. 

Read More
December 28th, 2024
 

Rikki Bannan – Don’t get caught up in momentum

Conference Fund Manager Rikki Bannan, Executive Director at IFM Investors, joins Equity Mates to discuss her standout 2023 stock pick, Telix, and explore what opportunities lie ahead.

Read More
December 19th, 2024
 

Professor Jane Butler: Sparking Hope for Spinal Cord Injuries

In this episode of the Hearts & Minds Podcast, we sit down with Professor Jane Butler to discuss her groundbreaking research into spinal cord injuries.

Read More
December 10th, 2024
 

Nick Griffin – The Nvidia story is not over

Nick Griffin, Founding Partner & Chief Investment Officer of Munro Partners joined the Equity Mates podcast in their Summer Series.

Read More
December 9th, 2024
 

HM1 CEO Succession

Hearts and Minds Investments Limited advises that Paul Rayson intends to retire from the position of Chief Executive Officer, effective 19 February 2025.

Read More
December 5th, 2024
 

Trump unifies top investors in decade-long bullish outlook for US

Nick Moakes, CIO of the $72 billion Wellcome Trust, told the conference that too many investors were banking on a return to the ultra-low interest rates that prevailed over the past decade.

Read More
November 20th, 2024
 

These rock-star stock picks could get markets talking next year

Eleven rock stars of international and local funds management took to stage – each tasked with picking and pitching one company whose shares will take off over the next year.

Read More
November 18th, 2024
 

Is anyone brave or stupid enough to bet against America?

Stock pickers have been punished for betting against the US. The choice between consensus and contrarianism on American exceptionalism is now harder than ever.

Read More
November 17th, 2024
 

Sohn: NYSE-listed Estee Lauder’s Northcape Capital pick

Northcape Capital’s Fleur Wright this gives a rare opportunity to buy a high quality company at an attractive price.

Read More
November 15th, 2024
 

Sohn ASX stock pick: Ellerston Capital’s Chris Kourtis backs Perpetual

Chris Kourtis has put his biggest bet on embattled Perpetual – picking one of the most hated stocks on the ASX – that he believes will soon be the ‘cheapest listed asset manager of scale in the universe’.

Read More
November 15th, 2024
 

AI start-ups a threat to incumbent big companies

Paul Bassat predicts emerging artificial intelligence companies will disrupt sectors and overtake established incumbent companies just as rapidly as the seismic shifts that took place when the internet emerged in the mid-1990s.

Read More
November 15th, 2024
 

Howard Marks and Sohn’s big stars reveal seven rules for investing

Among the stock picks and stunts at the Sohh Hearts & Minds event, Howard Marks and Nick Moakes provided investors with long-term rules for playing markets.

Read More
November 15th, 2024
 

Sohn investors position for bullish but bumpy Trump ride

Australia and the rest of the world must adjust to a new Trump presidency that will deliver an expected bull market but also disruption, with the leader in waiting prepared to “create pain” to get his way.

Read More
November 15th, 2024
 

Sohn stock picker experts name best shares to invest in for year ahead

‍Don’t overlook down and out silver miners, legacy skincare brands ready for a revival and a big financial company suffering from a severe case of shareholder wealth destruction.

Read More
November 15th, 2024
 

Eleven stock tips from Sohn to get you through 2025

“There’s no finer place for the finance festival than in the festival city,” said Matthew Grounds. He, along with fellow Barrenjoey co-executive chairman Guy Fowler and investor Gary Weiss, is one of Sohn’s driving forces.

Read More
November 15th, 2024
 

Sohn Hearts & Minds Investments fund targets $1.5bn valuation

‍Hearts & Minds Investments chair Chris Cuffe is hoping for HM1 to grow to more than $1.5bn in the next five years.

Read More
November 14th, 2024
 

Galaxy Digital CEO Mike Novogratz believes bitcoin will hit $US100k

Bitcoin’s bounce to record highs in recent days is only the beginning of a fresh surge higher for cryptocurrency, says US billionaire Mike Novogratz.

Read More
November 9th, 2024
 

Why this New York hedge fund manager sees opportunity in European stocks

Influential New York-hedge fund manager Ricky Sandler will turn to Europe for his next stock pick.

Read More
November 6th, 2024
 

Antipodes’ Ross says short-term wealth hinges on US election

The portfolio manager says defensive stocks pose a bigger risk than the magnificent seven for investors that are overexposed to the American sharemarket.

Read More
November 5th, 2024
 

Concentration risk key for investors: Antipodes Partners’ Vihari Ross

The concentration risk in global stock indexes that has built up during the strong rise over the past year must now be a key consideration for global investors, according to Vihari Ross.

Read More
November 5th, 2024
 

The fundie betting big on China – with help from AI

Mr Mehta is sticking to his well-worn strategy: he’s hunting for companies across Asia that aren’t battling intense competition and have management teams focused on costs, cash generation and high payouts to shareholders.

Read More
November 5th, 2024
 

Why this fundie wants you to ‘wince’ at his stock picks

When fund managers come to pitch their favourite stock at the annual Sohn Hearts & Minds conference, there are two ways they can go: they can play it safe, or they can take a risk and shock the room.

 

Read More
October 29th, 2024
 

IFM Investors’ Rikki Bannan backs small cap investments to rebound after mixed performance

IFM Investors executive director Rikki Bannan believes this year could be a good one to invest in some select small cap stocks.

Read More
October 27th, 2024
 

Meet the 2024 Conference Managers

Following a global search, the Conference Fund Manager Selection Committee is pleased to share eleven new managers for 2024. 

Read More
October 22nd, 2024
 

Chris Kourtis is on a winning streak. Here’s his next ASX pick

Chris Kourtis of Ellerston Capital thinks he’s found another winner and thinks it’s the last chance to have a bite at the cherry before the strategy plays out.

Read More
October 21st, 2024
 

Why Ellerston Capital’s Chris Kourtis plans to back a ‘hated’ stock

Chris Kourtis of Ellerston Capital plans to tip one of the “most hated” stocks in Australia when he presents at the 2024 Sohn Hearts & Minds Conference.

Read More
October 21st, 2024
 

Alex Pollak champions rewards of disruptive investment

Alex Pollak’s funds management company Loftus Peak rode the Nvidia wave and he is now looking at more opportunities in disruptive industry stocks.

Read More
October 14th, 2024
 

Buy Hold Sell: 2 Hall of Fame investors analyse each other's best ideas

Hall of Fame alumni Chris Kourtis of Ellerston Capital joins Livewire to analyse high conviction stock picks.

Read More
October 11th, 2024
 

Sumit Gautam - Why AI won't deliver in 2025 | Scalar Gauge

Sumit Gautam is the Founder of Scalar Gauge and speaks with Equity Mates ahead of his appearance at the Sohn Hearts & Minds conference.

Read More
October 8th, 2024
 

Missed out on Nvidia and Ozempic? This fundie says it’s never too late

Northcape Capital’s Fleur Wright is still kicking herself for not owning market darlings Nvidia and Novo Nordisk, the maker of the weight loss wonder drug Ozempic, before shares of those companies rocketed in 2023.

Read More
September 30th, 2024